Aura Biosciences (NASDAQ:AURA) Hits New 12-Month High After Analyst Upgrade

Aura Biosciences, Inc. (NASDAQ:AURA)’s share price reached a new 52-week high during mid-day trading on Friday after HC Wainwright raised their price target on the stock from $21.00 to $22.00. HC Wainwright currently has a buy rating on the stock. Aura Biosciences traded as high as $12.38 and last traded at $11.82, with a volume of 585739 shares changing hands. The stock had previously closed at $10.29.

A number of other equities analysts have also commented on AURA. Evercore ISI raised Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 9th. Finally, JMP Securities boosted their price target on shares of Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research report on Friday, September 13th. Three investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Aura Biosciences has an average rating of “Buy” and an average price target of $22.00.

Insiders Place Their Bets

In other news, CTO Mark Plavsic sold 7,383 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total value of $72,722.55. Following the completion of the sale, the chief technology officer now directly owns 121,132 shares of the company’s stock, valued at $1,193,150.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Aura Biosciences

A number of large investors have recently made changes to their positions in AURA. American Century Companies Inc. purchased a new stake in Aura Biosciences in the 2nd quarter worth about $119,000. American International Group Inc. boosted its holdings in Aura Biosciences by 27.4% during the 1st quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after acquiring an additional 3,782 shares during the period. Virtu Financial LLC bought a new position in Aura Biosciences in the 1st quarter valued at $144,000. SG Americas Securities LLC bought a new position in Aura Biosciences in the 3rd quarter valued at $169,000. Finally, Rhumbline Advisers increased its stake in Aura Biosciences by 39.6% in the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock worth $480,000 after purchasing an additional 18,011 shares during the period. 96.75% of the stock is owned by hedge funds and other institutional investors.

Aura Biosciences Price Performance

The firm has a market capitalization of $578.66 million, a P/E ratio of -5.53 and a beta of 0.37. The firm has a 50-day moving average price of $8.59 and a two-hundred day moving average price of $8.03.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.04. Sell-side analysts predict that Aura Biosciences, Inc. will post -1.7 earnings per share for the current fiscal year.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.